Circulating Hybrid Cells: A Novel Liquid Biomarker of Treatment Response in Gastrointestinal Cancers
Authors:
- 7 August 2021
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (13) , 8567-8578
Abstract
Real-time monitoring of treatment response with a liquid biomarker has potential to inform treatment decisions for patients with rectal adenocarcinoma (RACKeywords
Funding Information
- U.S. Department of War (W81XWH-18-1-0621)
- Oregon Health and Science University (Medical Research Foundation Early Clinical Investi)
- National Cancer Institute (P30 CA069533)
- Newton Esophageal Cancer Foundation (Esophageal Research Grant)
- Collins Medical Trust (Research Grant)
This publication has 46 references indexed in Scilit:
- The Basis of OncoimmunologyCell, 2016
- Tumor-Derived Exosomes and Their Role in Cancer Progression2016
- Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative managementBMC Cancer, 2015
- Importance of Surveillance and Success of Salvage Strategies After Definitive Chemoradiation in Patients With Esophageal CancerJournal of Clinical Oncology, 2014
- Single-Institution Retrospective Comparison of Preoperative Versus Definitive Chemoradiotherapy for Adenocarcinoma of the EsophagusAnnals of Surgical Oncology, 2014
- Quality of life of patients after low anterior, intersphincteric, and abdominoperineal resection for rectal cancer—a matched-pair analysisInternational Journal of Colorectal Disease, 2013
- Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancerBritish Journal of Surgery, 2012
- Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: An alternative to surgery?Journal of Surgical Oncology, 2011
- Hepatic Arterial Infusion Versus Systemic Therapy for Hepatic Metastases From Colorectal Cancer: A Randomized Trial of Efficacy, Quality of Life, and Molecular Markers (CALGB 9481)Journal of Clinical Oncology, 2006
- Assessing The Predictive Value of Clinical Complete Response To Neoadjuvant Therapy for Rectal Cancer: An Analysis of 488 PatientsJournal of the American College of Surgeons, 2002